Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Health-economic models of diabetes are complex since the disease is chronic, progressive and there are many diabetic complications. External validation of these models helps building trust and satisfies demands from decision makers. We evaluated the external validity of the IHE Cohort Model of Type 2 Diabetes; the impact of using alternative macrovascular risk equations; and compared the results to those from microsimulation models. METHODS: The external validity of the model was analysed from 12 clinical trials and observational studies by comparing 167 predicted microvascular, macrovascular and mortality outcomes to the observed study outcomes. Concordance was examined using visual inspection of scatterplots and regression-based analysis, where an intercept of 0 and a slope of 1 indicate perfect concordance. Additional subgroup analyses were conducted on 'dependent' vs. 'independent' endpoints and microvascular vs. macrovascular vs. mortality endpoints. RESULTS: Visual inspection indicates that the model predicts outcomes well. The UKPDS-OM1 equations showed almost perfect concordance with observed values (slope 0.996), whereas Swedish NDR (0.952) and UKPDS-OM2 (0.899) had a slight tendency to underestimate. The R2 values were uniformly high (>0.96). There were no major differences between 'dependent' and 'independent' outcomes, nor for microvascular and mortality outcomes. Macrovascular outcomes tended to be underestimated, most so for UKPDS-OM2 and least so for NDR risk equations. CONCLUSIONS: External validation indicates that the IHE Cohort Model of Type 2 Diabetes has predictive accuracy in line with microsimulation models, indicating that the trade-off in accuracy using cohort simulation might not be that large. While the choice of risk equations was seen to matter, each were associated with generally reasonable results, indicating that the choice must reflect the specifics of the application. The largest variation was observed for macrovascular outcomes. There, NDR performed best for relatively recent and well-treated patients, while UKPDS-OM1 performed best for the older UKPDS cohort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group (2004) · Diabetologia · doi:10.1007/s00125-004-1527-z · Cited by 615
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
Siebert, U., Alagoz, O., Bayoumi, A. M., Jahn, B., Owens, D. K., Cohen, D. J., & Kuntz, K. M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.014 · Cited by 588
Hayes, A. J., Leal, J., Gray, A. M., Holman, R. R., & Clarke, P. M. (2013) · Diabetologia · doi:10.1007/s00125-013-2940-y · Cited by 495
Eddy, D. M., Hollingworth, W., Caro, J. J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.012 · Cited by 466
Eeg‐Olofsson, K., Cederholm, J., Nilsson, P. M., Zethelius, B., Svensson, A. ‐., Gudbjörnsdóttir, S., & Eliasson, B. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02265.x · Cited by 178
Modelling Methods for Pharmacoeconomics and Health Technology Assessment: An Overview and Guide
Stahl, J. E. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826020-00004 · Cited by 171
An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study
Davis, W. A., Knuiman, M. W., & Davis, T. M. E. (2010) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.01958.x · Cited by 83
Cited by
Choi, J. G., Winn, A. N., Skandari, M. R., Franco, M. I., Staab, E. M., Alexander, J., Wan, W., Zhu, M., Huang, E. S., Philipson, L., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-2941 · Cited by 87
Cardiovascular risk in patients with type 2 diabetes: A systematic review of prediction models
Galbete, A., Tamayo, I., Librero, J., Enguita-Germán, M., Cambra, K., & Ibáñez-Beroiz, B. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109089 · Cited by 32
Liu, L., Ruan, Z., Ung, C. O. L., Zhang, Y., Shen, Y., Han, S., Jia, R., Qiao, J., Hu, H., & Guo, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01336-7 · Cited by 12
Metadata
- Authors
- Lundqvist, A., Steen Carlsson, K., Johansen, P., Andersson, E., & Willis, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-10-13
- Volume
- 9
- Issue
- 10
- Pages
- e110235
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2145216999
- Cited by
- 59
- References
- 10
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.